Abbott Laboratories (NYSE:ABT) Vs. Sigilon Therapeutics (NASDAQ:SGTX) Financial Analysis
Abbott Laboratories (NYSE:ABT) Vs. Sigilon Therapeutics (NASDAQ:SGTX) Financial Analysis
Abbott Laboratories (NYSE:ABT – Get Rating) and Sigilon Therapeutics (NASDAQ:SGTX – Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.
雅培實驗室（紐約證交所代碼：ABT-獲得評級）和西吉隆治療（NASDAQ：SGTX-獲得評級）都是醫療公司，但哪些是優越的股票？我們將根據股息，估值，機構所有權，分析師建議，盈利能力，風險和收益的實力來比較兩家企業。
Insider and Institutional Ownership
內幕和機構所有權
72.9% of Abbott Laboratories shares are held by institutional investors. Comparatively, 52.2% of Sigilon Therapeutics shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by insiders. Comparatively, 4.2% of Sigilon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
雅培實驗室 72.9% 的股票由機構投資者持有。相比之下，52.2％ 的 Sigilon 治療股票由機構投資者持有。亞培實驗室的 0.5％ 股份由內部人員持有。相比之下，4.2％ 的 Sigilon 治療股份由內部人員持有。強大的機構所有權表明，大型資金經理，對沖基金和捐贈基金認為股票將在長期內優於市場。
Profitability
盈利
This table compares Abbott Laboratories and Sigilon Therapeutics' net margins, return on equity and return on assets.
此表格比較了雅培實驗室和西吉隆治療的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Abbott Laboratories | 15.88% | 26.09% | 12.82% |
| Sigilon Therapeutics | -336.53% | -87.15% | -41.94% |
| 淨利潤 | 權益回報率 | 資產回報率 | |
| 雅培实验室 | 15.88% | 26.09% | 12.82% |
| 西吉隆治療 | -336.53% | -87.15% | -41.94% |
Analyst Recommendations
分析師推薦
This is a breakdown of current recommendations and price targets for Abbott Laboratories and Sigilon Therapeutics, as provided by MarketBeat.
這是由 MarketBeat 提供的雅培實驗室和西吉隆治療的當前建議和價格目標的細分。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Abbott Laboratories | 1 | 3 | 10 | 0 | 2.64 |
| Sigilon Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| 銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
| 雅培实验室 | 1 | 3 | 10 | 0 | 2.64 |
| 西吉隆治療 | 0 | 0 | 1 | 0 | 3.00 |
Abbott Laboratories currently has a consensus price target of $124.67, suggesting a potential upside of 27.38%. Sigilon Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 512.18%. Given Sigilon Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sigilon Therapeutics is more favorable than Abbott Laboratories.
雅培實驗室目前的一致價格目標為 124.67 美元，表明潛在的上行空間為 27.38％。西吉隆治療學的共識價格目標為 6.00 美元，表明潛在的上行空間為 512.18％。鑑於 Sigilon 治療的更強大的共識評級和更高的可能上行空間，分析師清楚地認為 Sigilon 治療比雅培實驗室更有利。
Earnings and Valuation
收益及估值
This table compares Abbott Laboratories and Sigilon Therapeutics' top-line revenue, earnings per share and valuation.
此表格比較了雅培實驗室和 Sigilon 治療的頂級收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Abbott Laboratories | $43.65 billion | 3.90 | $6.93 billion | $3.91 | 25.03 |
| Sigilon Therapeutics | $12.94 million | 2.46 | -$77.31 million | ($1.35) | -0.73 |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股盈利 | 市盈比率 | |
| 雅培实验室 | 四百三十六億五千萬 | 3.90 | 六百九十三億美元 | 3.91 美元 | 25.03 |
| 西吉隆治療 | 一百二十九萬元 | 2.46 | -77.31 百萬美元 | (一百三十五元) | -0.73 |
Abbott Laboratories has higher revenue and earnings than Sigilon Therapeutics. Sigilon Therapeutics is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.
雅培實驗室的收入和收益比西吉隆治療藥物更高。與亞培實驗室相比，Sigilon 治療以較低的價格盈利比進行交易，這表明目前兩隻股票中價格更便宜。
Volatility & Risk
波動性和風險
Abbott Laboratories has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, Sigilon Therapeutics has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.
雅培實驗室的測試版為 0.68，表明其股票價格的波動性比標普 500 低 32％。相比之下，西吉隆治療的測試值為 0.86，表明其股票價格的波動性比標普 500 小 14％。
Summary
摘要
Abbott Laboratories beats Sigilon Therapeutics on 10 of the 14 factors compared between the two stocks.
雅培實驗室擊敗西吉隆治療藥物 10 的 14 因素兩個股票之間的比較.
About Abbott Laboratories
關於雅培
(Get Rating)
(取得評分)
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1900 and is headquartered in Abbott Park, IL.
雅培實驗室從事廣泛且多元化的醫療保健產品系列的發現、開發、製造和銷售。它通過以下業務部門運營：成熟的醫藥產品，診斷產品，營養產品和醫療設備。成立的醫藥產品分部是指一系列品牌仿製藥產品的國際銷售。診斷產品部門銷售血庫、醫院、商業實驗室和替代護理測試場所的診斷系統和測試。營養產品部門迎合了成人和兒童營養產品的全球銷售。醫療設備部門包括用於治療心血管疾病的電生理學、心臟衰竭、血管和結構性心臟設備、糖尿病患者的糖尿病護理產品，以及用於治療慢性疼痛和運動障礙的神經調節設備。該公司由華萊士·卡爾文雅培於 1900 年成立，總部位於伊利諾伊州雅培公園。
About Sigilon Therapeutics
關於西吉隆治療
(Get Rating)
(取得評分)
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Sigilon 治療有限公司是一家臨床階段生物技術公司，為慢性疾病患者開發功能療法。其主要候選產品為 SIG-001，目前正在進行 I/II 期臨床試驗，以防止中度至重度血友病患者出血發作的 SIG-005。該公司還開發，用於治療 1 型粘多糖病的非神經學表現；SIG-007 提供持續和長期釋放功能酶，足以產生臨床益處和緩解下游治療的 Fabry ISlet 細胞的進展；提供功能酶的持續和長期釋放，以產生臨床益處和緩解法布里病細胞的下游治療方面的進展；提供功能酶的持續和長期釋放。1 型糖尿病。SIG-002Sigilon 治療公司與 Eli Lilly 和公司簽訂了研究合作和許可協議，用於治療 1 型糖尿病的 SLTX 產品候選產品的開發和商業化。該公司以前被稱為西吉隆公司，並在 2017 年 6 月更名為西吉隆治療公司。西吉隆治療有限公司成立於 2015 年，總部位於麻薩諸塞州劍橋。
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收雅培實驗室的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收雅培實驗室和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。